SCHEMBL20624601

SCHEMBL20624601

CC(O)(CC(=O)Nc1nc2ccc(Cl)nc2n1-c1ccc(F)cc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.35
▸ ALDH1A1 P00352 4/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ USP2 O75604 2/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ CASP1 P29466 2/20 0.33
▸ CASP7 P55210 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HIF1A Q16665 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ KLKB1 P03952 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ KCNQ3 O43525 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19277967 1.00 PPARG (0.35) PPARGALDH1A1MEN1USP2CYP1A2
SCHEMBL19276092 1.00 PPARG (0.35) PPARGALDH1A1MEN1USP2CYP1A2
SCHEMBL19276093 0.90 GRM5 (0.36) ALDH1A1MEN1USP2CYP1A2CYP2D6
SCHEMBL19276076 0.89 GRM5 (0.35) ALDH1A1MEN1CYP1A2TSHRKMT2A
SCHEMBL19278042 0.88 GRM5 (0.39) ALDH1A1MEN1USP2CYP1A2CYP2D6
SCHEMBL20624605 0.88 GRM5 (0.39) ALDH1A1MEN1USP2CYP1A2CYP2D6
SCHEMBL20624119 0.87 AKT1 (0.36) ALDH1A1MEN1TSHRKMT2AKLKB1
SCHEMBL19276101 0.87 AKT1 (0.36) ALDH1A1MEN1TSHRKMT2AKLKB1
SCHEMBL16084486 0.87 KCNQ2 (0.39) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL19277977 0.85 GRM5 (0.35) MEN1CYP1A2TSHRKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2023-01-05 — — US disclosed
US-20210130299-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 — — US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 PPARG 611/4885ALDH1A1 3093/4885MEN1 1284/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 PPARG 2520/4885ALDH1A1 1531/4885MEN1 2626/4885
US-20210130299-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 PPARG 611/4885ALDH1A1 3093/4885MEN1 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback